Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapport Therapeutics (RAPP) Preferred Stock Liabilities (2023 - 2024)

Rapport Therapeutics (RAPP) has 2 years of Preferred Stock Liabilities data on record, last reported at $145.3 million in Q1 2024.

  • On a quarterly basis, Preferred Stock Liabilities changed N/A to $145.3 million in Q1 2024 year-over-year; TTM through Mar 2024 was $145.3 million, a N/A change, with the full-year FY2023 number at $89.5 million, changed N/A from a year prior.
  • Preferred Stock Liabilities reached $145.3 million in Q1 2024 per RAPP's latest filing, up from $89.5 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for RAPP hit a ceiling of $145.3 million in Q1 2024 and a floor of $89.5 million in Q2 2023.